54 results about "Osteoclast cell differentiation" patented technology

Disclosed is an osteoblast differentiation promoting and osteoclast differentiation inhibiting agent which comprises a milk protein fraction having the following characteristics (1) to (4): (1) the milk protein fraction is derived from milk; (2) the milk protein fraction is a fraction containing a protein component having a molecular weight of 75,000 to 85,000 Daltons; (3) the milk protein fraction has a basic amino acid content of 13 to 15 wt % in the constitutional amino acid composition, and has a basic amino acid/acidic amino acid of 0.5 to 0.7; and (4) the milk protein fraction has an osteoblast differentiation promoting effect and an osteoclast differentiation inhibiting.

The invention discloses an application of a cyclic polypeptide CST-14 in preparation of a drug for treating osteoporosis. The CST-14 can be directly combined with a key receptor RANK in an osteoporosis process to antagonize an osteoclast induction function caused by RANKL and to play a protective role in the osteoporosis. An in vitro cell experiment result shows that the CST-14 can antagonize an osteoclast differentiation process caused by an osteoporosis key molecule RANKL. Meanwhile, an animal model shows that the CST-14 can inhibit the occurrence of the osteoporosis and improve disease conditions, does not have obvious toxic and side effects after long-term use, can be applied to the field of osteoporosis treatment and has broad application value and market prospect.

The invention discloses a new application of aurantiamide alcohol ester as an MMP-9 inhibitor. Under the condition that the aurantiamide alcohol ester has no cytotoxicity to osteoclast precursor cellsRAW 264.7, the capability of differentiation of RAW 264.7 cells induced by RANKL into osteoclasts is remarkably inhibited, and a certain concentration dependence is shown; follow-up research finds that the aurantiamide alcohol ester significantly reduces the expression of MMP-9 in the osteoclast formation process, thereby inhibiting osteoclast differentiation and formation. The invention discloses the application of the aurantiamide alcohol ester in preventing and treating osteolytic diseases, wherein the aurantiamide alcohol ester can be used for preventing and treating osteolytic diseases including bone destruction, osteoporosis and the like together with a medicine prepared from a conventional medicinal carrier. The invention provides a new medicine for preventing and treating osteoporosis, and has a great clinical application value.

The invention relates to medicine application, and specifically discloses application of acrylophenone amide derivates to the preparation of anti-osteoporosis medicine. The structural formula of the acrylophenone amide derivates is shown as formula (I) or formula (II). The compound is different from a molecular skeleton of medicine for preventing and treating osteoporosis used clinically at present, does not belong to a phosphate compound, and is neither estrogen medicine. Cytology experiment researches indicate that the compound can inhibit osteoclast differentiation so as to be of an anti-osteoporosis effect; cytotoxicity tests indicate that the compound is little in toxicity, and can be used for preventing and treating related diseases, particularly osteoporosis, caused by osteoclast prosoplasia.

The invention relates to application of recombinant IFN-lambda1 protein in preparation of a medicine for preventing and treating inflammation-induced bone loss, thereby solving a problem of bone metabolism imbalance caused by overactive osteoclasts triggered by release of a large number of inflammatory factors in a serious inflammatory bone loss state caused by bone infection. The applicant findsthat the recombinant IFN-lambda 1 protein can regulate and control the osteoclast differentiation and fusion process and reduce inflammatory factor release in the osteoclast differentiation process through experimental exploration, thereby solving a problem that osteoclasts are excessively activated in an inflammatory state and thus realizing the effect of protecting inflammatory bone loss.

The invention discloses application of graphene quantum dots to prevention and treatment of osteoporosis. The application of the graphene quantum dots to prevention and treatment of osteoporosis concretely comprises application of the graphene quantum dots to preparation of a drug for inhibiting fusion or differentiation and maturation of osteoclast precursor cells, application of the graphene quantum dots to preparation of a drug for resisting the bone resorption capacity of mature osteoclast, application of the graphene quantum dots to preparation of a drug for inhibiting differentiation and fusion of osteoclast or expression of ripening-associated genes, application of the graphene quantum dots to preparation of a drug for inhibiting TRAP enzyme activity of osteoclast, and application of the graphene quantum dots to preparation of a drug for inhibiting fusion of osteoclast precursor cells to form multinucleated mature osteoclast; an effective dose of the graphene quantum dots can inhibit differentiation and maturation of RANKL induced BMMs cells to osteoclast in a concentration-dependent manner, inhibit bone resorption capacity of osteoclast obtained by differentiation and maturation of the RANKL induced BMMs cells, and further inhibit fusion of osteoclast; besides, the graphene quantum dots can obviously reduce expression of osteoclast differentiation specific genes, therefore the graphene quantum dots finally achieve the function of preventing and treating osteoporosis, and further can be applied to prevention and treatment of osteoporosis.

The invention discloses application of a Flot2 inhibitor to inhibition of osteoclast formation and/or osteoclastic activity for the first time. The osteoclast generation and bone resorption induced byRANKL can be obviously reduced after the Flot2 expression is inhibited by Flot2-siRNA specific interference. A study team of the inventor discovers that the Flot2 directly participates in the osteoclast generation and bone resorption functions, and is possible to become a novel target of an osteoclast differentiation inhibitor. On the basis of the inhibition effect of Flot2-siRNA on osteoclasts and the application prospects of RNA interference medicine, the application of the Flot2 inhibitor as a medicine of inhibiting the osteoclast generation is provided.

The invention belongs to the technical field of osteoclast activation mechanism measurement, and discloses a measurement method for regulating an osteoclast activation mechanism in osseous metastasis.The method includes the steps of collecting data information of the lungs by a lung detection instrument; regulating osteoclast activation in osseous metastasis by RANK-RANKL; extracting myelomoncytes and differentiating the myelomoncytes to osteoclasts; judging whether a patient suffers from osseous metastasis or not by screening. The method can realize identification of osseous metastasis and healthy osseous metastasis bone tissue samples directly without sample pretreatment or normal temperature and pressure conditions, and has the advantages of simple operation, high precision and the like; myelomoncytes and mesenchymal stem cells are separated out at the same time, and primary myelomoncytes obtained by separation and purification can be successfully changed into osteoclasts by induced differentiation; meanwhile, data obtained after pretreatment and feature extraction is subjected to classification training by screening, and whether the patient suffers from osseous metastasis or not can be more conveniently and quickly judged.

The invention discloses application of a pregnane derivative in preparation of an osteoclast differentiation inhibitor. According to the application of the pregnane derivative in preparation of the osteoclast differentiation inhibitor, the structural formula of the pregnane derivative is shown as a formula 1. It is found through tests that the pregnane derivative has a direct and remarkable inhibiting effect on osteoclast differentiation, and therefore the pregnane derivative can serve as an osteoclast differentiation inhibitor medicine to be used for treating various diseases such as osteoporosis caused by osteoclast differentiation.

The invention discloses an application of vanilline in preparation of an osteoclast differentiation inhibitor. According to the application of the vanilline in preparation of the osteoclast differentiation inhibitor, wherein the structural formula of the vanilline is shown as a formula 1. It is found through tests that vanilline has a direct and remarkable inhibition effect on osteoclast differentiation, and therefore vanilline can serve as an osteoclast differentiation inhibitor medicine to be used for treating various diseases such as osteoporosis caused by osteoclast differentiation.

The invention discloses application of proteus mirabilis outer membrane vesicle in preparation of a medicine for preventing or treating osteolytic diseases. The proteus mirabilis outer membrane vesicle inhibits miR96-5p expression and promotes Abca1 expression, thereby inhibiting an MAPK/ERK pathway and causing osteoclast differentiation to be blocked; the proteus mirabilis outer membrane vesicle induces release of MPT-related cytochrome c to cause a mitochondrial structure to be damaged, increase production of active oxygen and cause increase of osteoclast apoptosis. The proteus mirabilis outer membrane vesicle not only significantly inhibits differentiation and functions of RANKL-induced osteoclasts in vitro, but also can improve bone metabolism imbalance caused by OVX and bone erosion caused by CII in vivo, and provides a new idea for preventing or treating the osteolytic diseases.

The invention discloses an application of Urolithin B in preparation of a medicine/health care product for preventing and treating osteoporosis, the Urolithin B is a product generated by converting ellagic tannin rich in pomegranate, walnut and berry through intestinal flora, and has the biological activities of inflammation resistance, oxidation resistance, cancer resistance and the like. In the research of the invention, OVX (ovariectomy) induced mouse osteoporosis model and in-vitro bone marrow-derived macrophages (BMMs) and RAW264.7 cell induced osteoclast differentiation are used for researching the treatment effect of UB on osteoporosis, and the mechanism of UB in inhibiting osteoclast differentiation is further discussed. According to the research, the urea stone B has a considerable application prospect in preparation of the medicines/health-care products for preventing and treating osteoporosis, and is relatively high in safety.

The invention discloses an application of alkaloid in preparation of an osteoclast differentiation inhibitor. According to the application of the alkaloid in preparation of the osteoclast differentiation inhibitor, the alkaloid is a compound AP-123/40765213 or AE-562/43462182, and a structural formula of the alkaloid is shown as a formula 1. Tests find that the compounds AP-123/40765213 and/or AE-562/43462182 have a direct and remarkable inhibition effect on osteoclast differentiation, so that the compounds can be used as osteoclast differentiation inhibitor drugs for treatment of various diseases caused by osteoclast differentiation, such as osteoporosis.